<SEC-DOCUMENT>0001193125-19-297010.txt : 20191121
<SEC-HEADER>0001193125-19-297010.hdr.sgml : 20191121
<ACCEPTANCE-DATETIME>20191121065719
ACCESSION NUMBER:		0001193125-19-297010
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20191121
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191121
DATE AS OF CHANGE:		20191121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		191235688

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d817874d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20191121" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form 8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2019-11-21_to_2019-11-21">AMGEN INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2019-11-21_to_2019-11-21">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2019-11-21_to_2019-11-21">0000318154</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="amgn-20191121.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2019-11-21_to_2019-11-21"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-11-21</xbrli:startDate> <xbrli:endDate>2019-11-21</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-11-21</xbrli:startDate> <xbrli:endDate>2019-11-21</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A1.250SeniorNotesDue2022Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-11-21</xbrli:startDate> <xbrli:endDate>2019-11-21</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-11-21</xbrli:startDate> <xbrli:endDate>2019-11-21</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="font-size:10pt;width:8.5in;margin:0 auto"> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <p style="margin-bottom:0px;margin-top:4pt"></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">UNITED STATES</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">SECURITIES AND EXCHANGE COMMISSION</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Washington, D.C. 20549</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0px;margin-top:12pt">Form <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2019-11-21_to_2019-11-21">8-K</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">CURRENT REPORT</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Pursuant to Section 13 OR 15(d)</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">of the Securities Exchange Act of 1934</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2019-11-21_to_2019-11-21" format="ixt:datemonthdayyearen">November 21, 2019</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:24pt;margin-bottom:0px;margin-top:12pt"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Amgen Inc.</span> </p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">(Exact name of registrant as specified in its charter)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2019-11-21_to_2019-11-21" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2019-11-21_to_2019-11-21">001-37702</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2019-11-21_to_2019-11-21">95-3540776</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(State or other jurisdiction</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">of&#32;incorporation)&#160;</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Commission</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">File Number)&#160;</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(IRS Employer</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Identification No.)&#160;</p></td></tr>
<tr style="font-size:1pt;">
<td colspan="3" style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2019-11-21_to_2019-11-21">One Amgen Center Drive</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2019-11-21_to_2019-11-21">Thousand Oaks</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2019-11-21_to_2019-11-21" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td>&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2019-11-21_to_2019-11-21">91320-1799</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Address of principal executive offices)</p></td>
<td>&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Zip Code)</p></td></tr></table> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt">Registrant&#8217;s telephone number, including area code</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2019-11-21_to_2019-11-21">(805)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2019-11-21_to_2019-11-21">447-1000</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2019-11-21_to_2019-11-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2019-11-21_to_2019-11-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2019-11-21_to_2019-11-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2019-11-21_to_2019-11-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table> <p style="font-family:Times New Roman;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:12pt">Securities registered pursuant to Section 12(b) of the Act:</p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Title of each class</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Trading</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Symbol(s)</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Name of each exchange</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">on which registered</p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common stock, $0.0001 par value</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember" format="ixt-sec:exchnameen">The NASDAQ Global Select Market</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">1.250% Senior Notes Due 2022</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">AMGN22</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">2.000% Senior Notes Due 2026</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">AMGN26</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></p></td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p> <p style="font-family:Times New Roman;text-align:right;font-size:10pt;margin-bottom:0px;margin-top:12pt">Emerging growth company&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2019-11-21_to_2019-11-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Times New Roman;font-weight:normal">&#9744;</span></p> <p style="margin-bottom:0px;margin-top:10pt"></p> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <div></div> <p style="margin-top:0"></p></div>

<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;2.01&#32;</td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Completion of Acquisition or Disposition of Assets</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt">On November 21, 2019 (the &#8220;<span style="text-decoration:underline">Closing</span>&#8221;), Amgen Inc. (&#8220;<span style="text-decoration:underline">Amgen</span>&#8221;) completed the acquisition of certain assets and liabilities associated with the worldwide rights to OTEZLA<sup style="font-size:85%;vertical-align:top">&#174;</sup> (apremilast) from Celgene Corporation (&#8220;<span style="text-decoration:underline">Celgene</span>&#8221;) pursuant to an Asset Purchase Agreement (as amended, the &#8220;<span style="text-decoration:underline">APA</span>&#8221;), dated August&#160;25, 2019, between Amgen and Celgene, a copy of which was attached to the Current Report on Form <span style="white-space:nowrap">8-K</span> filed by Amgen on August&#160;26, 2019. The parties entered into Amendment No.&#160;1 to the APA on October&#160;17, 2019, a copy of which was attached to the Current Report on Form <span style="white-space:nowrap">8-K</span> filed by Amgen on October&#160;18, 2019. Amgen and Celgene entered into the APA in connection with the merger between Celgene and Bristol-Myers Squibb Company, which was completed on November 20, 2019. </p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;7.01. </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Regulation FD Disclosure.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt">Amgen has issued a press release regarding the Closing, which is attached hereto as Exhibit&#160;99.1 and incorporated into this Item 7.01 by reference. </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">The information contained in this Item 7.01 and Exhibit&#160;99.1 shall not be deemed to be &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing. </p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;9.01. </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Financial Statements and Exhibits.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">(a) Financial Statements of Businesses Acquired. </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">Amgen intends to file financial statements in accordance with Item 9.01(a) as part of an amendment to this Current Report on Form <span style="white-space:nowrap">8-K</span> no later than 71 calendar days after the required filing date for this Current Report on Form <span style="white-space:nowrap">8-K. </span></p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">(b) Pro Forma Financial Information. </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">Amgen intends to file pro forma financial information in accordance with Item 9.01(b) as part of an amendment to this Current Report on Form<span style="white-space:nowrap">&#160;8-K</span> no later than 71 days after the required filing date for this Current Report on Form <span style="white-space:nowrap">8-K. </span></p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;">d)&#32;</td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Exhibits</td> </tr> </table>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td></td>
<td></td>
<td></td>
<td style="width:5%;"></td>
<td style="width:92%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td colspan="2" style="vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Exhibit <br />No. </p> </td>
<td style="vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Description </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">99.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d817874dex991.htm">Press Release, dated November 21, 2019. </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">104 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document).</p> </td> </tr> </table> <div></div> <p style="margin-top:0"></p>
 </div>



<p style='page-break-before:always'> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">SIGNATURES </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:0px;margin-right:auto">
<tr>
<td style="width:45%;"></td>
<td style="width:1%;"></td>
<td style="width:4%;"></td>
<td></td>
<td style="width:3%;"></td>
<td style="width:1%;"></td>
<td style="width:44%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td colspan="3" style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">AMGEN INC. </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Date:&#160;November 21, 2019 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">By:</p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;margin-bottom:1pt;font-size:10pt;margin-top:0pt;border-bottom:1px solid #000000">/s/ Jonathan P. Graham </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:bottom;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Jonathan P. Graham </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Executive Vice President, General Counsel and Secretary </p> </td> </tr> </table> <div></div> <p style="margin-top:0"></p>
 </div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d817874dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">


<IMG SRC="g817874g1121085319745.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Amgen Center Drive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thousand Oaks, CA
91320-1799</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1000</FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.Amgen.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B><I>News Release</I></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMGEN COMPLETES ACQUISITION OF OTEZLA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>(APREMILAST) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Differentiated Therapy Strengthens Amgen&#146;s Long-Standing
Expertise in Inflammation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THOUSAND OAKS, Calif. (Nov. 21, 2019) - Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of
worldwide rights to Otezla<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (apremilast), the only oral, <FONT STYLE="white-space:nowrap">non-biologic</FONT> treatment for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (NASDAQ:CELG) in connection with its previously announced
merger with Bristol-Myers Squibb Company (NYSE:BMY), which was completed on Nov. 20. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Otezla is an important treatment in the post-topical, <FONT
STYLE="white-space:nowrap">pre-biologic</FONT> segment in its approved indications in the U.S., including the treatment of patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> plaque
psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Beh&ccedil;et&#146;s Disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Otezla is approved in more than 50 markets outside the U.S., including the&nbsp;European Union&nbsp;and&nbsp;Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;As the prevalence of chronic inflammatory diseases increases worldwide, Otezla represents a unique opportunity to further Amgen&#146;s mission of
bringing innovative medicines to patients, while building on our long-standing expertise in inflammation,&#148; said Robert A. Bradway, chairman and chief executive officer at Amgen. &#147;We look forward to working with the dedicated professionals
joining us from Celgene to help realize the global potential of Otezla as an important option for patients.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing of the Otezla acquisition
offers Amgen many potential benefits including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A strong strategic fit with Amgen&#146;s long-standing expertise in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> plaque psoriasis and active psoriatic arthritis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A differentiated, oral therapy complementary to Amgen&#146;s existing inflammation franchise of innovative
biologics and biosimilar products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">At least low double-digit percentage Otezla sales growth, on average, anticipated over the next five years.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected acceleration of Amgen&#146;s near- and long-term revenue growth. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Worldwide rights which fit well with Amgen&#146;s international presence and global expansion objectives.
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN COMPLETES ACQUISITION OF OTEZLA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(APREMILAST) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This move also provides Amgen with an important strategic product offering new opportunities for growth
and serving patients,&#148; Bradway said. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of the Acquisition and 2019 Guidance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Otezla, along with certain related assets and liabilities, was acquired for $13.4&nbsp;billion in cash, or approximately $11.2&nbsp;billion, net of the present
value of $2.2&nbsp;billion in anticipated future cash tax benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the closing of the Otezla acquisition, the Company is updating its overall 2019
guidance. For the full year 2019, the Company now expects total revenues in the range of $23.1&nbsp;billion to $23.3&nbsp;billion. Previously, the Company expected total revenues in the range of $22.8&nbsp;billion to $23.0&nbsp;billion. On a GAAP
basis, the Company now expects earnings per share (EPS) in the range of $12.50 to $12.75. Previously, the Company expected GAAP EPS in the range of $12.50 to $12.80. The updated GAAP guidance reflects charges between close and the end of the year
related to the intangibles and inventory acquired. On a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis, the Company now expects EPS in the range of $14.50 to $14.70. Previously, the Company expected
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> EPS in the range of $14.20 to $14.45. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
OTEZLA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(apremilast) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OTEZLA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(apremilast) 30 mg tablets is an oral small-molecule inhibitor of phosphodiesterase 4
(PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels, which is thought to indirectly modulate the production of inflammatory mediators. The specific mechanism(s) by which OTEZLA
exerts its therapeutic action in patients is not well defined. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. INDICATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Otezla<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(apremilast) is indicated for the treatment of patients with moderate to severe plaque
psoriasis who are candidates for phototherapy or systemic therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Otezla is indicated for the treatment of adult patients with active psoriatic
arthritis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Otezla is indicated for the treatment of adult patients with oral ulcers associated with Beh&ccedil;et&#146;s Disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. IMPORTANT SAFETY INFORMATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contraindications
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Otezla<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(apremilast) is contraindicated in patients with a known hypersensitivity to
apremilast or to any of the excipients in the formulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warnings and Precautions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diarrhea, Nausea and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla. Most events occurred within the first few
weeks of treatment. In some cases patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea,
or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or
vomiting. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN COMPLETES ACQUISITION OF OTEZLA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(APREMILAST) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depression: Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of
depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or
other mood changes, and they should contact their healthcare provider if such changes occur. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Psoriasis: Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.3%
(12/920) of patients reported depression compared to 0.4% (2/506) on placebo. Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in
0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Psoriatic Arthritis: Treatment with Otezla is associated with an increase in depression. During clinical trials,
1.0% (10/998) reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of patients on Otezla, compared to none in placebo-treated patients. Depression was
reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo-treated patients (0/495). Two patients who received placebo committed suicide compared to none on Otezla. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Beh&ccedil;et&#146;s Disease: Treatment with Otezla is associated with an increase in depression. During the
clinical trial, 1% (1/104) reported depression or depressed mood compared to 1% (1/103) treated with placebo. No instances of suicidal ideation or behavior were reported in patients treated with Otezla or treated with placebo. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Psoriasis: Body weight loss of <FONT STYLE="white-space:nowrap">5-10%</FONT> occurred in 12% (96/784) of patients
treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>10% occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with
placebo. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Psoriatic Arthritis: Body weight loss of <FONT STYLE="white-space:nowrap">5-10%</FONT> was reported in 10%
(49/497) of patients taking Otezla and in 3.3% (16/495) of patients taking placebo. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Beh&ccedil;et&#146;s Disease:&nbsp;Body weight loss of &gt;5% was reported in 4.9% (5/103) of patients taking
Otezla and in 3.9% (4/102) of patients taking placebo. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drug Interactions: Apremilast exposure was decreased when Otezla was <FONT
STYLE="white-space:nowrap">co-administered</FONT> with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is
not recommended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adverse Reactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Psoriasis:
Adverse reactions reported in <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5% of patients were (Otezla%, placebo%): diarrhea (17, 6), nausea (17, 7), upper respiratory tract infection (9, 6), tension headache (8, 4), and headache (6, 4). </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN COMPLETES ACQUISITION OF OTEZLA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(APREMILAST) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Psoriatic Arthritis: Adverse reactions reported in at least 2% of patients taking Otezla, that occurred at a
frequency at least 1% higher than that observed in patients taking placebo, for up to 16 weeks (after the initial <FONT STYLE="white-space:nowrap">5-day</FONT> titration), were (Otezla%, placebo%): diarrhea (7.7, 1.6); nausea (8.9, 3.1); headache
(5.9, 2.2); upper respiratory tract infection (3.9, 1.8); vomiting (3.2, 0.4); nasopharyngitis (2.6, 1.6); upper abdominal pain (2.0, 0.2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beh&ccedil;et&#146;s Disease: Adverse reactions reported in at least <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>5% of patients taking Otezla, that occurred
at a frequency at least 1% higher than that observed in patients taking placebo, for up to 12 weeks were (Otezla%, placebo%): diarrhea (41.3, 20.4); nausea (19.2, 10.7); headache (14.4, 10.7); upper respiratory tract infection (11.5, 4.9); upper
abdominal pain (8.7, 1.9), vomiting (8.7, 1.9); back pain (7.7, 5.8); viral upper respiratory tract infection (6.7, 4.9); arthralgia (5.8, 2.9). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use
in Specific Populations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pregnancy: Otezla has not been studied in pregnant women. Advise pregnant women of the potential risk of fetal loss. Consider
pregnancy planning and prevention for females of reproductive potential. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Otezla during pregnancy. Information about the registry can be obtained by calling <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-877-311-8972</FONT></FONT></FONT> or visiting&nbsp;<U>https://mothertobaby.org/ongoing-study/otezla/</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lactation: There are no data on the presence of apremilast or its metabolites in human milk, the effects of apremilast on the breastfed infant, or the effects
of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother&#146;s clinical need for Otezla and any potential adverse effects on the breastfed child from Otezla or from the
underlying maternal condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Renal Impairment: Otezla dosage should be reduced in patients with severe renal impairment (creatinine clearance less than
30 mL/min); for details, see Dosage and Administration, Section&nbsp;2, in the Full Prescribing Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please&nbsp;<U>click here</U>&nbsp;for
Otezla<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;Full Prescribing Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Otezla<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;is a&nbsp;registered trademark. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Financial Measures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this news release, management has presented earnings per share guidance for 2019, in accordance with U.S. Generally Accepted Accounting Principles (GAAP)
and on a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis. This <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure is computed by excluding certain items related to acquisitions, restructuring and certain other items from the
related GAAP financial measures. A reconciliation for this <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure to the most directly comparable GAAP financial measure is included in the news release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that its presentation of <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures provides useful supplementary information to
and facilitates additional analysis by investors. The Company uses certain <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures to enhance an investor&#146;s overall understanding of the financial performance and prospects for the
future of the Company&#146;s ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses the <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures set forth in the news release in connection with its own budgeting
and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial
measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN COMPLETES ACQUISITION OF OTEZLA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(APREMILAST) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Amgen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering
innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve
people&#146;s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world&#146;s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with
breakaway potential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, visit www.amgen.com and follow us on <U>www.twitter.com/amgen</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amgen Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release
contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements
on the outcome, benefits and synergies of collaboration with any other company, including anticipated Otezla sales growth and the timing of <FONT STYLE="white-space:nowrap">non-GAAP</FONT> EPS accretion, as well as estimates of revenues, operating
margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such
estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent
annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent periodic reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and current reports on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> Unless otherwise
noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product
candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new
indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be
perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied
and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through
licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of
entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. The acquisition of Otezla may result in unanticipated costs,
delays or other operational or financial problems related to integrating the Otezla business with our company, which may divert our management&#146;s attention from other business issues and opportunities and restrict the full realization of the
anticipated benefits of the transaction within the expected timeframe or at all. Further, failures or difficulties in integrating or retaining new </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN COMPLETES ACQUISITION OF OTEZLA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(APREMILAST) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 6
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
personnel or in integrating the operations of the Otezla business, products or assets we acquire (including related technology, commercial operations, compliance programs, manufacturing,
distribution and general business operations and procedures, and failures or difficulties relating to any transition services agreements, supply agreements, toll manufacturing agreements, and intellectual property licensing and transfer agreements)
may affect our ability to realize the benefits of the transaction and grow our business, and may result in us incurring asset impairment or restructuring charges. These and/or other challenges may arise in connection with our acquisition of Otezla
or other acquisition activities, which could have a material adverse effect on our business, results of operations and stock price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our results may be
affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from
other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies
imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare
cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations,
litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the
protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our
commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and
product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts
for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our
products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies or products, and to
integrate the operations of companies or in support of products we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our
data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.
We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONTACT:&nbsp;Amgen,&nbsp;Thousand Oaks </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jessica Akopyan, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-0974</FONT></FONT> (media) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trish Hawkins, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">805-447-5631</FONT></FONT> (media) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arvind Sood,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">805-447-1060</FONT></FONT> (investors) </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AMGEN COMPLETES ACQUISITION OF OTEZLA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(APREMILAST) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 7
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of GAAP EPS Guidance to Non-GAAP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EPS Guidance for the Year Ending December 31, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GAAP diluted EPS guidance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Known adjustment to arrive at non-GAAP*:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition-related expenses (a)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost savings initiatives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-GAAP diluted EPS guidance</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The known adjustments are presented net of their related tax impact, which amount to approximately $0.41 per
share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The adjustments relate primarily to non-cash amortization of intangible assets acquired in business
combinations. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may
occur subsequent to this press release such as acquisitions, collaborations, asset impairments, litigation and changes in the fair value of our contingent consideration. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amgn-20191121.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.12 - Release 2019.3 -->
<!-- Creation date: 11/21/2019 4:53:28 PM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:amgn="http://www.amgen.com/20191121"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.amgen.com/20191121"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
    <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20191121_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20191121_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20191121_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="amgn_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="amgn_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="amgn_A1.250SeniorNotesDue2022Member" name="A1.250SeniorNotesDue2022Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="amgn_A2.00SeniorNotesDue2026Member" name="A2.00SeniorNotesDue2026Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>amgn-20191121_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.12 - Release 2019.3 -->
<!-- Creation date: 11/21/2019 4:53:30 PM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20191121.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="amgn-20191121.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="amgn-20191121.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="amgn-20191121.xsd#amgn_A1.250SeniorNotesDue2022Member" xlink:type="locator" xlink:label="amgn_A1.250SeniorNotesDue2022Member" />
    <link:loc xlink:href="amgn-20191121.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="amgn_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A1.250SeniorNotesDue2022Member" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A2.00SeniorNotesDue2026Member" order="26" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="29.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="30.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>amgn-20191121_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.12 - Release 2019.3 -->
<!-- Creation date: 11/21/2019 4:53:28 PM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="amgn-20191121.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="amgn_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="amgn-20191121.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="amgn_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:loc xlink:href="amgn-20191121.xsd#amgn_A1.250SeniorNotesDue2022Member" xlink:type="locator" xlink:label="amgn_A1.250SeniorNotesDue2022Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_A1.250SeniorNotesDue2022Member" xlink:to="amgn_A1.250SeniorNotesDue2022Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_A1.250SeniorNotesDue2022Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 1.250 Senior Notes Due 2022 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_A1.250SeniorNotesDue2022Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 1.250 Senior Notes Due 2022 [Member]</link:label>
    <link:loc xlink:href="amgn-20191121.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="amgn_A2.00SeniorNotesDue2026Member" xlink:to="amgn_A2.00SeniorNotesDue2026Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="amgn_A2.00SeniorNotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 2.00 Senior Notes Due 2026 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="amgn_A2.00SeniorNotesDue2026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 2.00 Senior Notes Due 2026 [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>amgn-20191121_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Addin 62.6.8.12 - Release 2019.3 -->
<!-- Creation date: 11/21/2019 4:53:29 PM Eastern Time -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="amgn-20191121.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="amgn-20191121.xsd#amgn_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="amgn_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20191121.xsd#amgn_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="amgn_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="amgn_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20191121.xsd#amgn_A1.250SeniorNotesDue2022Member" xlink:type="locator" xlink:label="amgn_A1.250SeniorNotesDue2022Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A1.250SeniorNotesDue2022Member" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="amgn-20191121.xsd#amgn_A2.00SeniorNotesDue2026Member" xlink:type="locator" xlink:label="amgn_A2.00SeniorNotesDue2026Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="amgn_A2.00SeniorNotesDue2026Member" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="amgn_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="52.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g817874g1121085319745.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g817874g1121085319745.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% ,L# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBF-+&IPTB@^A- #Z*.HR** "BBB@ HHHH
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MH;^'K&34-.66[DA#R.78')Y['MG%6[_P)X9ATZZECTJ-72)V4^8_! ..]=8
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,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>8
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d817874d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 4,
   "dts": {
    "definitionLink": {
     "local": [
      "amgn-20191121_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "d817874d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20191121_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20191121_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "amgn-20191121.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 2,
   "memberStandard": 1,
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20191121",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d817874d8k.htm",
      "contextRef": "duration_2019-11-21_to_2019-11-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d817874d8k.htm",
      "contextRef": "duration_2019-11-21_to_2019-11-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 3,
   "tag": {
    "amgn_A1.250SeniorNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "A 1.250 Senior Notes Due 2022 [Member]",
        "terseLabel": "A 1.250 Senior Notes Due 2022 [Member]"
       }
      }
     },
     "localname": "A1.250SeniorNotesDue2022Member",
     "nsuri": "http://www.amgen.com/20191121",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_A2.00SeniorNotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "A 2.00 Senior Notes Due 2026 [Member]",
        "terseLabel": "A 2.00 Senior Notes Due 2026 [Member]"
       }
      }
     },
     "localname": "A2.00SeniorNotesDue2026Member",
     "nsuri": "http://www.amgen.com/20191121",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "amgn_DocumentAndEntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationLineItems",
     "nsuri": "http://www.amgen.com/20191121",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "amgn_DocumentAndEntityInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationTable",
     "nsuri": "http://www.amgen.com/20191121",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>d817874d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20191121"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amgn-20191121.xsd" xlink:type="simple"/>
    <context id="duration_2019-11-21_to_2019-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A1.250SeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2019-11-21_to_2019-11-21"
      id="Hidden_dei_EntityRegistrantName">AMGEN INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2019-11-21_to_2019-11-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2019-11-21_to_2019-11-21"
      id="Hidden_dei_EntityCentralIndexKey">0000318154</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2019-11-21_to_2019-11-21">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2019-11-21_to_2019-11-21">2019-11-21</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2019-11-21_to_2019-11-21">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2019-11-21_to_2019-11-21">001-37702</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2019-11-21_to_2019-11-21">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2019-11-21_to_2019-11-21">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2019-11-21_to_2019-11-21">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2019-11-21_to_2019-11-21">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2019-11-21_to_2019-11-21">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2019-11-21_to_2019-11-21">(805)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2019-11-21_to_2019-11-21">447-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2019-11-21_to_2019-11-21">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2019-11-21_to_2019-11-21">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2019-11-21_to_2019-11-21">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2019-11-21_to_2019-11-21">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_us-gaap-CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">1.250% Senior Notes Due 2022</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">AMGN22</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A1.250SeniorNotesDue2022Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">2.000% Senior Notes Due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2019-11-21_to_2019-11-21_us-gaap-StatementClassOfStockAxis_amgn-A2.00SeniorNotesDue2026Member">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2019-11-21_to_2019-11-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MKC_\KL*^LV[G_K'Q15#5\.LNU!=02P,$%     @ *3=U3YE<G",0!@  G"<
M !,   !X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T
M$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY
M\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2
MP]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?
M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA
M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M
M&N#C\7@XMLO2BW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_K
MFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K
M>A(5M>5 TR  6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T
M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)
MI#-ZG7TZSFN4?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R
M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MXFC8_7=S,J67=ROQ'FM;MOW?:'ULG:V&+GXI5?Y^N19U?SU?GF2CH0P7T%!
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M*,W6=;<3?]]<SH27@;.'X;R;7 _=R_]02P,$%     @ *3=U3_6,^("4 @
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MD&G&8]B@,)*1M&FRE;2"4!2KOBUX5;%N]_N]&8UAO%:J0./_^;SHN\JHC,M
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M7H(PK8>_R43]-<#JUV5?4$L#!!0    ( "DW=4\+C]@#(0$  %<$   3
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M+G)E;'-02P$"% ,4    "  I-W5/)^B'#H(   "Q    $
M@ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "DW=4_6*G<V[P
M "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( "DW=4^97)PC$ 8  )PG   3              "  ;<"  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ *3=U3QIV5UT* P  @ \  !@
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9>&UL4$L%!@     *  H @ (  +<4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6604958352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 21, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMGEN INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 21,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amgn_A1.250SeniorNotesDue2022Member', window );">A 1.250 Senior Notes Due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.250% Senior Notes Due 2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member', window );">A 2.00 Senior Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amgn_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">2.000% Senior Notes Due 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amgn_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amgn_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A1.250SeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A1.250SeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-19-297010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-19-297010-xbrl.zip
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MT%?=+96&%Z^=5@J_Z.3D)#2_/INJYE/Y;+O.IA.N?E2F G>%:>J*)684*D@
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MPRU5]IP[%G(AKX1FZBQF%:=2^="R@)C5%F.VD8J%4E$I.;.DV_\!A&(18C^
M3)2G9MIRUI4L@\M9GW \V]"PJ/C_L9KK1/JXSWW=K1V6]GAXW*.RP\.:0VBL
M16&R&0Y6I $'@GI  BL245J*\42QRWBGJVM.:0_Z;0D)$!1;0FO1P^^<:$"4
M"+A//CGF)QG:=9Q?DI&+6D0U!"IY3!M'NE#_]9.[[QR?E*-Z#D[+ [?[O*!5
M\D$;#3V-R"#;714;8[-, \.=-NWQ8%B[!UE7Y(KUR:WHT?#8E/4M'BT1^,<S
M:!]GF'N81\<I; KU/ZXN[L_/R-U]X_[\[HUAN3MO_G%[<7]Q?D<:5V?D_,_F
MWQI77\Y)\_KR\N+N[N+ZZL4 K"P%X#^HZO*PHT6X0\Y*S1*I.'O5(PO46M*X
M/QXD8&U=0[V;$D]WCFQ"6.#LC:13FNY,\PS0N6@-%@KLR_)\, U=P8;<<P/)
M,^'%:'XSP?;RP9H)Y">CM VOEA;_'%Z!>MZ>7]V3V_.;Z]O[-U;&FUBJF(::
M:$'NF(>R0-Q=<GU+W+TM?_N-H1-MHKL, 8LEUQS&.Q]X71IV&&EXFD"Q>[1;
M?54@<QB*+@;"<LLB(3792I\9!1>#*4W8 W1-I"EF_G;M<4V],7[*N75?5E59
M8C.1IP4^T#4?W3IHWO7I< @0L;!0OQ(/U@^LN#L$&VX4?!EYJ%27DP=RHB(:
MIL,33" 7^:!HLUJUQQ*/]09FY,E%Z)5.RM@1^I\O)."Y7N*,%FZ=#RAH&THI
MBK4<P4NH(BIB'@8?/N$AX5H1T$^0<KG] \@09K1I*V#$8T$ K/#,>I)3,,\1
M]?WTV<)F/L[$!X=C7]D304 CQ2 <BBAH,4L+DKYK>2[S?$F;I=$,V@6+A+3_
M_!0Z.\IN]9=C=)VUGQ1G/T]5W9VJ.EGL+BS--(8_"2PRK1/1#BNV)*/?<2T)
M@MD:?1#<GQ;3PE37#TQJ[M$@D2B@R7'"$:!BX2W59:YQM^H.BBTDS 3&B)NH
MNRGB4,MA4_A/,O5H9S ZUBR2X@&'15M_Q@+:![.?9^)S.)9#UK%B+%/[8S#A
M,P\8E&%.9O7%"[>X>W#@5#84S5+TG@XNDD249TBX)GF/]HJ[>U7GX&!_+GW7
M,B*'[\.&+!?#;QF[0(0D OQ?2?X%[J_RN7'/7\H96 XRT?[UTV[EF&>-V'9V
MXOQX\K\D2W!YA"OUYAQ TT6L<OT<A+^XO2/GO2@00TPTOR7I)PT<N1*E:0[D
MF*:,H<V:(/ %T;D_+>R.?,;$^W7WP=5;P*FG5GL&'RP'^ \[<35\7S*EDG]?
M(0QQ5YZTKD-&;-C6-$"2,\D?<EVN=T^')GR\EO>B'ZY,A?NNB!4-?7)-OZL/
MB;R9=J_E#?C/W&RO>FYOO E80*60TT>\QZ4-M<7Y(VC8C0!R!/_DT3J!3OW(
MW:TX1??@*#=9]4Q^X?NP:TO.BPE9,24321!7'M& L 'S8@W&![Z&B8JI[74%
MZQUA"C)#4&BV)UD-?S [\WJ2GY/K&R?O?OUT6'$/CA71+&!15\"4$!HO;8<
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M257IV!,//^#!JT@;2L)V$JDACN\''[9V-_!#.89"RY CS-T@.UL"/?=U&J3
M^!' #:[J(HQ)Z"DW!)K1,VD"N XG3LR0BKBN5R__K^CE7_^)O/RV$XCI2/42
M:BG/Q%J723 &?I!%P$8N[;T!I8;?W)EU6BX@TYEMC&4J3$WR=!@BCV+Y0HF#
M5_14PSH!Z&]81P;"IZ"R^:!1\)/H%G0=V=E94>AF8?5.:O0D/70A #!HMDPS
M1XQ#+<+@DFK')%TAPJ-@DW,<@7>;2%@.-U2B+K8W+!6ICI4<XK2L7#Z;YDB1
M+]F-08_RP 8^+R#D^.@&L4<2#K5W=%G02K B,(O&(*RXKMCX0:BCEN+NIMP:
M).])C<TH4KPIC$Y6QV%6*$8.QG0'@?74.$<A'58B4?'B'%+S8+TV43' T37"
MILZ!H$L#=%+EC2+&H0G,H-"^0?DCVMM;K89!?32&L)M:9.K[*+^=)1_= . &
M5M)GX>FK"8;GP9 JST&:3$3]PT:4YX&>>A]=4Z&M579H+!,PD?Q\%L[PT 5L
M1<]J, 'TY/7D=P1P*AX)#8GMW0I>V>=V7&"S+JK)+BC!#79H"KQ53-I;Q5@7
MBT/LB9L1QKS[2O>.I==(^0D^LT)/W^_.?+)$!SKNCWQUP?)Q'!/7N4"M?4QG
M\@+N_U[5+J_7J,(368FY5&$Y-"O3^<J(,E"AZ5/:C/$;&NW7M*6RBC%5MH"9
M--"N]2N0 ^C\^7@-8Z%25*LP#=$SF@M$Q\@H&S1K=26>]?/Y"K[V[UAY46=$
M#3G_I5XSNS 4WLB=LM33<!HI #5S1@\02?;MO3^F(F!J-L%4-RW/E'?.F]%Y
MV;4I2X.Q,7^^JY\7:'Z)8A*0FIL:P;]@;U$?0&/-</>XAK5=4,XP$E$=,C5S
MH -$+RXJG0W;5) V5[0+@&5Z\+-KZ!:J(68446J1=7=.T-_.%_]P1CY76>?)
M][E]A0W.T2SS:,X,CGUL&T887Z$BL8NF0O7Q1 7C?I9H=B<5C#MR[A19-F\#
M"Y3KM1PR^(M92--1Y R\!_,U#D$8%.L%\M)SO,R)#&?NV5B\B@;;-J 6D%%M
M!] #\"%\A9@7%[/[9I/.KW&A@*#R;1S><$4U6G?V A<.3 .I!B$[C8B\BE/C
M#2WD8\&R*NSQ""971F#'-Y%R8;OC^_&MW5K^F\4U&TA NX5BU*FQ;P//K>@Q
M _^].+!E(H\>:&OY;TT[T->(7/5TV-<!<C6PM+!MO]/YV*?"AT,^I4(DS[4,
MQ>93_'>%2[+TCQ5'2DDY2B5J6L@%^F '6'>,:5M(/]S!3PW/M6>/<A=T&T9F
M#&DR;N)2L/MJ2=@9!X-M[Y+DFWX!/>PDGK\K&_X<9A@]2:T2AMIN@>PQP9'O
M5N 04D"ZE'%2(M5<4VL!;,'<Q!0-TJ.)@P2H\1 16E\;PL:$W$",Y=W#*#SC
M(F\Y%/.V,ZCWN6L:[#T+N $.A%?W@(UT^<8Z7">Z2-6$6MS99KG8;-0R@UV*
MW#&=F :.W-P,!X[B?&PC53%")]&DS J7/N3-T&;L1N)^T%RP&Z+]R.C6ED!4
MA5@Q7KQ'D.4S,DA!!1C =-F]P*\ .^0;I!K(AF]Q;3\F"LCWH.6 J8-CBA2E
M+[MP;NTHC\8:=XLS1%S;*&-?8!ZS.Q14M),!^8W990);2!%!&T0,V.+PWQGW
MO\6V<X9!&@][0C(()22 F0B(V\D1LH#./$8)AV^9)85TV20M!Z:P[E[,LS'=
MZ3+M>@&I5%7+BEGT]$VK7R<'^7XS5&WB_*3'=+<9GAHJ[?8./?0G7LDDH/0@
M&.Q:&<$K[/4@^"MW#)ZZWEK$&YKB$.%!N<VWUI44D:$DI&4&!&CD#U(I(+!F
MKD8746*&<D#I20/;;_B*S61N*H<X!$K$) XX\15V@X)3A:0L-,7O+AP^&R.<
M1Y"5HP3[E-1K(<C[2+.;MJ"#Z0;1#*AH>A1,&-QXO1? #&B$HQEGMV=Q:BSP
M;RHY)GIF[R ,2D.9!E,@ZY 'X2&#'$<4RGO-\@$E;#<G] ;;C&S D9-/%P@"
MX:4-I1!H\ T"CXDG4#*B40@5]:0AEYEQE<;<7Z6X3%2H=8P9@4X":*,5&S8Y
MI?E2(!6Z,,]%_).*#P(6W@^1#KCU7Y9?.U/5*N#T6/ER*8U3@J7!$$9CII[R
MS:16!<9=&\$&^)I%12W9 Y4%B_&! N4T%VNYQQU1K:B.NG47PF.(1$-6<HLM
MHIW[WFW1J>S<1Y1E$OKU6'UR@4IK>J,2:K*3$&%X:6Y8T,TRJVV6^J0;+1/U
MYC3O,<W7S#DA1L&,(BA*#8V(M(!1RMS/;F@];Q,-.#-(Y)CQ+$6_>(&)#V00
MLB\Y(;F+8H861YU=<WC%F#R'_,JV?']U(/]Z#N2-G\B!3.J QA!4:'IR5<F_
M$*TK]XS/ TI.]2,63:WXKY7M 2X6<P;HN(SSMC6*RE,^5</T!S1AFA@6--85
MQR_R.4P1"OJ9:P8RY#2&V;%&CH!ZRF<#G2.^<^B:Q80)D4539A_,BNF>!HJ3
M#1-E_2,47)Z6ODI!U%9=U86?N18,%"T4[1GS8G2M3D4NK4F(X\RHZ.<O+Z'S
M 28C:43,UFHP:5RZ?_,N)DC@2L"@QO?SLR1%O2QB*'< [$M:$1YO,>6+.%XQ
M@\*TE"<1QB;?BI-#\%N(.J'1C3!>/#,&2EN:)?VHXR2/5?P]=UU88<12G+0#
MZ4RD2N:>O8HUWWPQ:EU&')W&F#4-,DB]0-_A+"E9>JBU\V&S-EXY\5P31:6=
M% A0^@&,*(#(J+AEH_GHV;$N>(N)[FH?- V<RLOBU^FW!2/*.G:"/(1?"MX[
M#:CDM2-WFD=6G0@EV'LCOF/6/$OAY#1P:H+MK^>6GG.3_)(_>*]$O63LD0H4
M1!42+.IFI9N+  =C[(OM,C$U]7"U@6>["T2-TA"84ULX&T01D^^L,?Q<<.8Q
M!\KZV$E>>PEPK6AJP%OTP^'S8"-H,$W'G$S=QPSL(/&745U&.W=*/0]S2 S1
MO(\,8X$57*'%&T0P/S/04!HT9J7,%Z7>@]H1?;^\E_S8*_B B64<TBBA [MW
M&+-N8Q4V(8A\-/CHTN'24O*D7OR(WG2=6O<.M],UJAAZ_AIT I@Q)!-OA(5[
MA-T-"_M&P1C,G9=%@DY*EHFZH=*_*V4WC+B'\<?B5E I SVC .HY5E]3G!9X
MB@4K<DP+UL(0G-AC'%^HN2.J#//F5M;&"YV-ZH4R&%=1,[YG1N3]TC=7+!M'
M#MX_$V(29NBZW+C$?Q1Z>?X3/9E?JU-0B[DY)\AZL#,!W.@T,.8Z*N&1232Z
M17)%\4^*._R:*GN7P8"20@V;L^.8#LC$8B:%QL%FLTZP^$@68%$'?.T)NBN"
MQ,O&5YPD:4:U3"9&,J*N/C00:@/LCU)7^">7;^@*7YLGM.W!D9%NO#<V346:
MS/$Q9E0:'H)8[E2?BIY0<,5341.<UZ5R&5<5/SDL\RS#B@-Q'G@QBW"ZKXHC
MG&Q: OMPUC:Y'@3:6 8?C+TV<P4-<ZW2.&"WLM%T$%[HH:..YSEO=+F3/*@5
M"\7CI^.N>.<*;*2"VM<FPR@U>3G%:%%@PJA4L&2(>6S:IO.6D T4Q$LQP&-;
MO_K..\J)!+<\GOD%L@[OJ;%W(J^=9H&ZJ8F;&P/?]$ "#AX1  #TP-%ODP.Q
M(L1HQDX=8WOL K,W/V+"X7X9MD[Y)2RVH1]+*B@BC/.H@("3##BF)-W2AO6-
MURM D2E#RB FF&;&AY?#!YMC%2(X99^'=+S*>M;@,$P0GI#=;=GF!Q 14WHC
M>@70N1M*+N?/7<D/U.(<^A&CLQ*LQ',JNEXQ=E56]YA_P]@41R'OI'69611,
MG&U3Q<:XZ/CA/#KT,+-%I6;84Z57 Z8NBC 5H&"]@/92I081G_&QY\H?94N@
M"\&/KX%PO&D?)TJQVH_&SD,UFD-D4WK<*<NX%%"X*+6#W,G1@+U@$@5/PQB&
M^!HQ&.205B@9C+3.8 X?PIECE1'#LZ _HYL?U$982JCF:1Y21-D8(Y<P,L=H
M*F*UZ!WGY5MK*&%>Q:A07M^'&!4/^'! F=-8RX:.206(ASH(>J]PQR0V*CKV
M!,V5T@.),L2DK$@9(VAQG\UZ[7=5/"1IFMY+.BL&KPD:$YN 0PVL"YOKB>@*
M/N=H'<BK.+&#9"RSK(_JF8T1ZT[RR'NTL/?FS9OG#Y#MGY[TNOL]TXB%H[/\
M=V\49QIA=BHO]1U[?Q+GR/]BAT%/BNYE/)E*H*FGJ#_<:JTO=SJ;RZWMS4ZE
MJG"1+FY:>NYM]<#L'HG/\OJ2TA<>6#%YYZ[MIM8WUMK_F4UU\?),7US$L=]X
MP,5N#SZF=FNC5=V1*P)8>O7O_H+^W<V?R+\+!W%>KD8"\>?ND'3WN()8L55O
M]R41/]6R2O-;9?P;WAQZR.4L!\I3I .LM1M\[>P+K6SQ:R3!L@)59"9>%89;
M_>Z^<=5V;M5V;R6*+[2%>]I^<Q793DR!6LGMF3]<6[>MC;<+W(K,_6([M_%6
M%PH-X/8*W=[N_OO/.QAU7,L!(CY\(I[\?N$-Z'!@';BCF--K3SSN*/8J2W?M
M\![3 <]\A1Q^I]ULM=1X%S3)FW0YH#SGG67[Y6,I@OB"'X149(F$:RM++7D4
MV_M5H&_0_W8;P.IS?[GC1XNI=%/]PAY==5M\_.3T]W-8XNRIOV=Q#QYP]H.5
M]?[VIKW>WOWAN5X&LIOKCUL<48JADMLLLH#;GP^//GWN 2\ID6'A:] 6D"G"
M-)TG?63&"G\%JOT;738H_7]EFMNSHP6:4,4&&(\V%?JO.T])Q,_QVW_]W$7\
M_-GDS-J386PW#^@NVT0!2JG'8J5%N?14*'KO$U66V-SJO,J:9X3N]@_+F_]Z
MVMC'>*B65^2>YQ:(F!.I_QO8]F,QIM5L/5)#>>7M_VG\[<F;@B+RJZ+MQL^)
MMC.4^IM=<0O=GA*XC\7:?ISX*N$(!.#GY 8#J4! ;UKT7]$'\Y^?]@G/^!5.
MKW Z^#F5HR<U=9WS^L_DI.J\.JF>#;*;CX3LSRO/UI@1^'&&\?^78T"/F??/
MP:E?(?7?"BD3C'EWUQU./Q",^ZDO<>K<>4_37XLG>??%2X^^:^EA\ADX:WE)
MF%1X67%-<R)DWLPT4JE)YPN2O&H(C$C.:K95'B:?%OW:6$E[0WTIPJGX2ZO9
M:0OJCD^=4.?>I/0KH "Y3O^,2% \?CYC3!"$B0+N:(@1"NRB@L><I(5BSR!*
M930,D(>8<C.;&HDIE#9'D/*K^T%DTSH?<YG6O"Y!106V\_8[RGKF*JEY7PS3
MJ+70)]WE;!0AEH(R-+2I\J:/!??IE]-ZC6[%*+8:H<:Q 7=:S1MR4$FTU)66
MN-4B\6K1%WQ5J5/@'BNN[GX #PIL'ZE<(GA,G82IP87IR%[N7#TC@PKT]M.#
M;_#EY]Z7X[W_!U!+ 0(4 Q0    ( "DW=4_.^.FD/00  /81   1
M      "  0    !A;6=N+3(P,3DQ,3(Q+GAS9%!+ 0(4 Q0    ( "DW=4_A
M7_F=X04  !DV   5              "  6P$  !A;6=N+3(P,3DQ,3(Q7V1E
M9BYX;6Q02P$"% ,4    "  I-W5/1//UH?<'  "N60  %0
M@ & "@  86UG;BTR,#$Y,3$R,5]L86(N>&UL4$L! A0#%     @ *3=U3TIJ
MO4N:!0  Y#D  !4              ( !JA(  &%M9VXM,C Q.3$Q,C%?<')E
M+GAM;%!+ 0(4 Q0    ( "DW=4^)[80] Q(  #B*   .              "
M 7<8  !D.#$W.#<T9#AK+FAT;5!+ 0(4 Q0    ( "DW=4_(<[Q<Q28  ,*\
M   1              "  :8J  !D.#$W.#<T9&5X.3DQ+FAT;5!+!08
..!@ & (,!  ":40     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>4</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d817874d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com//20191121/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d817874d8k.htm">d817874d8k.htm</File>
    <File>amgn-20191121.xsd</File>
    <File>amgn-20191121_def.xml</File>
    <File>amgn-20191121_lab.xml</File>
    <File>amgn-20191121_pre.xml</File>
    <File>d817874dex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
